Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C
Bristol-Myers Squibb Co. will collaborate with a unit of Johnson & Johnson to study a potential combination therapy for chronic hepatitis C.
The companies will test the potentially positive effects of combining Johnson & Johnson's drug TMC435 with Bristol-Myers Squibb's daclatasvir. The clinical trials will begin in the first half of 2012 and will include a combination of the two drugs, the drugs plus pegylated interferon and ribavirin, and the drugs plus ribavirin.
The terms of their partnership were not disclosed.